iRegene Therapeutics Co., Ltd

CHENGDU, China, Feb. 23, 2026 /PRNewswire/ -- The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. and China. Concurrently, the company's "AI + Chemical Induction" platform saw its first U.S. patient dosed for Parkinson's disease at Weill Cornell Medical Center and its first patient enrolled for Multiple System Atrophy (MSA) at Beijing Tiantan Hospital. These parallel milestones for NouvNeu001 and NouvNeu004 represent the next phase of iRegene's global strategy, transitioning from early safety data into mid-stage clinical trials designed to rigorously evaluate therapeutic efficacy across international patient cohorts. First Patient Dosed in U.S. Phase IIa Trial of NouvNeu001 for Parkinson 's Disease NouvNeu001 is an investigational off-the-shelf cell therapy derived from induced pluripotent stem cells (iPSCs) and chemically induced into dopaminergic progenitor cells. The therapy was administered via stereotactic neurosurgery into the bilateral putamen at Weill Cornell Medical Center in the first patient of an open-label U.S. Phase II study. Building on positive Phase I data, the U.S. Food and Drug Administration (FDA) cleared NouvNeu001 for direct Phase II entry in the Q3 2025, following Fast Track Designation (FTD) and Regenerative Medicine Advanced Therapy (RMAT) designation. This progression validates iRegene's preclinical and clinical package and robust CMC framework, enabling closer FDA collaboration and accelerated pathways. NouvNeu001 is designed to address the underlying pathology of Parkinson's disease by replacing lost dopaminergic neurons and modifying disease progression — a "single dose, sustained benefit" approach aimed at addressing critical unmet needs. With the first patient dosed in U.S., parallel Phase II trials continue in both the U.S. and China. First Patient Enrolled in China for MSA Trial with NouvNeu004 In parallel, iRegene has enrolled the first patient in a randomized controlled clinical trial in China evaluating NouvNeu004, its allogeneic iPSC-derived off-the-shelf cell therapy candidate for Multiple System Atrophy (MSA). Led by Principal Investigator Professor Yilong Wang at Beijing Tiantan Hospital, Capital Medical University, the study marks a significant advancement for MSA – a rapidly progressive neurodegenerative disorder with no approved disease-modifying therapies. NouvNeu004 employs a dual "neurotrophic support + neural reconstruction" strategy, providing trophic support to affected brain regions while promoting functional neural differentiation to potentially halt or reverse progression. China's NMPA approved the integrated Phases I–III trial application in October 2025, while the U.S. FDA has granted a special exemption and cleared an international Phase I trial, enabling efficient simultaneous development in both countries. "Dosing the first U.S. patient for Parkinson's disease and enrolling the first MSA patient in China are pivotal milestones in our mission to deliver transformative, disease-modifying therapies to patients worldwide," said Dr. Meng Cai, Chief Medical Officer of iRegene Therapeutics. "These parallel advances reflect the productivity of our 'AI + Chemical Induction' platform, yielding two pioneering 'off-the-shelf' cell therapies: NouvNeu001 for Parkinson's disease and NouvNeu004 for Multiple System Atrophy. Together, they demonstrate our commitment to a robust global development pathway and our continued contribution to the advancement of cell therapy for neurodegenerative diseases." The "AI + Chemical Induction" Advantage: From Proof-of-Concept to Industrial Validation iRegene's core strategy centers on its proprietary "AI + Chemical Induction" platform, engineered to bring scalability and consistency to cell therapy manufacturing. While traditional differentiation methods frequently rely on complex growth factors and commercial media cocktails – which are often prone to batch-to-batch variability and high costs – iRegene utilizes algorithm-optimized small molecule combinations to direct cellular differentiation toward specific lineages. This chemical induction approach is designed to reduce batch-to-batch variability and support consistent manufacturing under a stable CMC framework, facilitating true off-the-shelf production at lower costs with reduced supply chain complexity compared to personalized or growth factor-dependent therapies. The platform's foundational technology has been granted patents across China, Japan, and the U.S. Building on this foundation, iRegene is developing a pipeline of universal, iPSC-derived cell therapies for currently incurable diseases, led by its flagship program and several novel candidates: NouvNeu001 for Parkinson ' s disease – The world's first clinical-stage, allogeneic iPSC-derived, chemically induced dopaminergic progenitor cell therapy for PD; holds dual FDA FTD (August 2025) and RMAT (December 2025) designations; IND cleared in both China and the U.S.; now in Phase II trials in both China and the U.S. NouvNeu003 for early-onset Parkinson ' s disease – The company's second product candidate. IND approved by China's NMPA (December 2023); Phase I completed in China. NouvNeu004 for Multiple System Atrophy – World's first "AI + Chemical Induction"-derived cell therapy to enter clinical development for MSA; IND approved by China NMPA covering Phases I–III; U.S. FDA special exemption and international Phase cleared; first patient enrolled in China randomized trial. NouvSight001 for Retinal Degenerative Diseases (RDDs) – U.S. FDA Orphan Drug Designation granted (March 2024); advancing as an innovative ophthalmology therapy. This expanding pipeline underscores the versatility of iRegene's underlying technology, demonstrating the platform's capacity to deliver a new generation of scalable cell therapies for complex neurodegenerative disorders. As these candidates move into advanced clinical stages, they represent a tangible shift toward establishing chemically induced iPSC-derived treatments as a safe and effective pillar of global regenerative medicine. About iRegene Therapeutics Founded in 2017 by a team of international professionals, iRegene Therapeutics is a pioneer in applying "Chemical Induction" to precisely reprogram cell fate and optimize cellular functions for innovative cell therapies. Leveraging its proprietary "AI + Chemical Induction" platform, iRegene has built a robust pipeline targeting currently incurable diseases, including Parkinson's disease and Multiple System Atrophy. SOURCE iRegene Therapeutics Co., Ltd. 21% more press release views with Request a Demo

NouvNeu001 is intended for the treatment of Parkinson’s disease. Credit: meeboonstudio / Shutterstock.com. iRegene Therapeutics has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its lead product, NouvNeu001, aimed at treating Parkinson’s disease. This marks the first instance of an allogeneic induced pluripotent stem cell (iPSC)-derived cell therapy receiving both fast track and RMAT designations from the FDA, with the former awarded in August 2025. The FDA introduced the RMAT designation, a regulatory pathway, under the 21st Century Cures Act. It is intended to expedite the development and evaluation of regenerative medicine therapies intended for serious or life-threatening diseases. Therapies receiving this designation may have earlier engagement with the agency and could qualify for accelerated approval and priority review. NouvNeu001 is designed to address neuronal loss and support the restoration of natural dopamine production by targeting neuronal degeneration at its root. Phase I data showed significant clinical efficacy, including improvements in movement disorder society-unified Parkinson’s disease rating scale (MDS-UPDRS) Part III motor scores. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence iRegene chief medical officer Dr Meng Cai said: “The RMAT designation is a pivotal regulatory advancement for NouvNeu001 and a strong endorsement of its clinical value. “This designation reflects the FDA’s recognition of NouvNeu001’s potential to address a serious unmet medical need in Parkinson’s disease and provides a structured framework for deep, efficient collaboration with the agency. “We are committed to leveraging this opportunity to accelerate our global clinical development programme and bring this transformative therapy to patients as early as possible.” Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free eBook Navigating cell therapy process development The cell therapy manufacturing sector is rapidly evolving, driven by the need to balance innovative process development with rigorous GMP standards. This eBook, brought to you by industry leaders Cytiva, explores how biotech firms can address common challenges — including minimizing contamination risks from manual processes, overcoming resource limitations, and creating scalable, robust designs. Industry experts discuss strategies including automation, strategic outsourcing, and flexible equipment selection to streamline processes and reduce regulatory risks. To unlock expert insights on optimizing your cell therapy pathway from clinical development to commercialization, fill in your details now. Thank you. You will receive an email shortly. Please check your inbox to download the eBook. By Cytiva Thematic You have a right to withdraw your consent at any time, by clicking here . We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our privacy policy .

None\n Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in Parkinson’s disease, following compelling Phase I clinical dataiRegene Therapeutics has reached a definitive regulatory turning point, securing the U.S. FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for its lead product, NouvNeu001, for the treatment of Parkinson’s disease (PD).This milestone makes NouvNeu001 the first allogeneic iPSC-derived cell therapy globally to hold both FDA Fast Track Designation (FTD) and RMAT designations, following the FTD granted in August 2025. This \"regulatory double-play\" formally validates three key elements: iRegene’s promising clinical data, its innovative chemical induction platform, and the therapy’s potential to modify the course of Parkinson’s disease. It also provides an accelerated path to market, bridging the gap between compelling evidence and widespread patient access.The RMAT designation is a special regulatory pathway established by the U.S. FDA under the 21st Century Cures Act. It is designed to accelerate the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure serious or life-threatening diseases. Products granted RMAT designation may receive benefits such as early, frequent, and close interaction with the FDA, as well as potential eligibility for accelerated approval pathways and priority review. This collaborative regulatory framework is expected to significantly shorten the timeline from clinical development to market, advancing iRegene’s mission to bring transformative therapies to patients worldwide.Regulatory Validation of Clinical EfficacyThe FDA’s decision to grant RMAT status was driven by robust Phase I clinical data demonstrating that NouvNeu001 does more than manage symptoms—it has the potential to fundamentally modify the course of Parkinson\'s disease. Significant Motor Improvement: In the low-dose cohort, patients experienced an average 30.6-point improvement (52.82%) in MDS-UPDRS Part III motor scores (OFF state) at 12 months. The high-dose cohort showed improvements of 23.3 points (OFF) and 9.67 points (ON) at 9 months.Sustained Benefit: Clinical improvements continued through 15 months post-treatment, suggesting successful long-term survival and maturation of the engrafted neurons.Expedited Timeline: RMAT status grants iRegene intensive and frequent interaction with the FDA and potential eligibility for accelerated approval and priority review, significantly shortening the development-to-market timeline.Addressing a Fundamental Unmet Need in Parkinson’s DiseaseParkinson’s disease is the second most prevalent neurodegenerative disorder globally. Existing therapies primarily focus on symptomatic relief or complication management, rather than modifying or reversing disease progression.NouvNeu001 was developed to directly address this fundamental treatment gap. As an iPSC-derived, allogeneic dopaminergic progenitor cell therapy, it is designed to replace lost dopaminergic neurons, restore disrupted neural circuits, and enable patients to regain endogenous dopamine production. By targeting the root cause of neuronal degeneration, NouvNeu001 represents a first-in-class, disease-modifying approach with the potential to fundamentally change the PD treatment standard.A Growing Pipeline: A Commitment to Patients Across Disease StatesiRegene\'s vision extends beyond a single product. The company is committed to leveraging its unique \"AI + Chemical Induction\" platform to build a robust pipeline of universal iPSC-derived therapies for currently \"incurable\" diseases.Building on the success of NouvNeu001, iRegene is advancing a growing pipeline featuring: NouvNeu004: Recently received I-III all-stage IND approval from the NMPA, making it the world\'s first cell therapy product for Multiple System Atrophy (MSA) and iRegene\'s third self-developed product to enter clinical trials.NouvNeu003: The company\'s second product targeting early-onset Parkinson\'s disease, which entered Phase I trials in December 2023.NouvSight001: A breakthrough ophthalmology product that was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024 for retinal degenerative diseases.These expanding pipelines underscore iRegene\'s long-term commitment to patients and the company\'s confidence in its platform to generate a new generation of transformative therapies - bringing scalable, safe, and effective cell treatments to those who need them most.About iRegene TherapeuticsFounded in 2017 by a team of international professionals, iRegene Therapeutics is the world’s earliest biotech to apply \" Chemical induction\" to precisely reprogram cell fate and optimize cellular functions for their innovative cell therapy products. Leveraging this breakthrough platform, iRegene has built a robust pipeline targeting currently \"incurable\" diseases including Parkinson\'s disease (PD) and blindness. As a leader in “chemical induction”, iRegene’s proprietary system enables the efficient easy generation of human specific cell types with high purity, and enhanced cellular functionality, pioneering the next generation of chemically derived cell therapies.